A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia

A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia

Abstract Background Despite recent approval of several new agents, relapsed acute lymphoblastic leukemia (ALL) remains challenging to treat. Sapanisertib (MLN0128/TAK‐228) is an oral TORC1/2 inhibitor that exhibited preclinical activity against ALL. Methods We conducted a single‐arm multi‐center Pha...

Full description

Bibliographic Details
Main Authors: Aref Al‐Kali, Ibrahim Aldoss, Pamela J. Atherton, Carrie A. Strand, Bijal Shah, Jonathan Webster, Bhavana Bhatnagar, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Sarah A. Buhrow, Jianping Kong, Joel M. Reid, Alex A. Adjei, Scott H. Kaufmann
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Cancer Medicine
Subjects:
acute lymphoblastic leukemia
ALL
mTOR inhibitor
sapanisertib
Online Access:https://doi.org/10.1002/cam4.6701

Internet

https://doi.org/10.1002/cam4.6701

Similar Items